Multivariate analysis comparing MSD vs URD vs mmRD with known 7/8 or 8/8 matches (mmRD subgroup)
| Outcome . | mmRDsub vs MSD . | URD vs MSD . | URD vs mmRDsub . | |||
|---|---|---|---|---|---|---|
| RR (95%CI) . | P . | RR (95%CI) . | P . | RR (95%CI) . | P . | |
| Acute GVHD 2-4* | 2.09 (1.39-3.14) | < .001 | 1.79 (1.44-2.22) | < .001 | 0.86 (0.55-1.33) | .491 |
| Acute GVHD 3-4† | 2.68 (1.48-4.86) | .001 | 2.64 (1.83-3.78) | < .001 | 0.98 (0.52-1.86) | .960 |
| Chronic GVHD‡ | 3.51 (2.21-5.58) | < .001 | 4.05 (3.12-5.27) | < .001 | 1.15 (0.71-1.88) | .564 |
| TRM§ | 2.16 (1.16-4.00) | .015 | 3.17 (2.33-4.32) | < .001 | 1.47 (0.77-2.79) | .242 |
| Relapse‖ | 0.69 (0.41-1.16) | .162 | 1.05 (0.81-1.35) | .724 | 1.52 (0.86-2.69) | .146 |
| Disease-free survival¶ | 1.05 (0.71-1.57) | .802 | 1.35 (1.12-1.62) | .002 | 1.28 (0.84-1.95) | .256 |
| Overall survival# | 1.17 (0.77-1.77) | .456 | 1.43 (1.15-1.77) | .001 | 1.22 (0.79-1.89) | .368 |
| Outcome . | mmRDsub vs MSD . | URD vs MSD . | URD vs mmRDsub . | |||
|---|---|---|---|---|---|---|
| RR (95%CI) . | P . | RR (95%CI) . | P . | RR (95%CI) . | P . | |
| Acute GVHD 2-4* | 2.09 (1.39-3.14) | < .001 | 1.79 (1.44-2.22) | < .001 | 0.86 (0.55-1.33) | .491 |
| Acute GVHD 3-4† | 2.68 (1.48-4.86) | .001 | 2.64 (1.83-3.78) | < .001 | 0.98 (0.52-1.86) | .960 |
| Chronic GVHD‡ | 3.51 (2.21-5.58) | < .001 | 4.05 (3.12-5.27) | < .001 | 1.15 (0.71-1.88) | .564 |
| TRM§ | 2.16 (1.16-4.00) | .015 | 3.17 (2.33-4.32) | < .001 | 1.47 (0.77-2.79) | .242 |
| Relapse‖ | 0.69 (0.41-1.16) | .162 | 1.05 (0.81-1.35) | .724 | 1.52 (0.86-2.69) | .146 |
| Disease-free survival¶ | 1.05 (0.71-1.57) | .802 | 1.35 (1.12-1.62) | .002 | 1.28 (0.84-1.95) | .256 |
| Overall survival# | 1.17 (0.77-1.77) | .456 | 1.43 (1.15-1.77) | .001 | 1.22 (0.79-1.89) | .368 |
MSD indicates matched sibling donor transplant; URD, 8/8 matched unrelated donor transplant; mmRDsub, 8/8 parents or 7/8 sibs/parents; RR, relative risk; CI, confidence interval; GVHD, graft-versus-host disease; and TRM, treatment-related mortality.
Adjusted for total body irradiation use and stratified by GVHD prophylaxis.
Adjusted for year of transplantation and stratified by GVHD prophylaxis.
Adjusted for donor-recipient sex match, recipient age at transplantation, GVHD prophylaxis, and antithymocyte globulin use.
Adjusted for recipient age at transplantation, performance score, disease, and year of transplantation.
Adjusted for total body irradiation use in conditioning and stratified by performance score, disease, disease status, and interval from diagnosis to transplantation.
Adjusted for recipient age at transplantation and stratified by performance score, disease, and disease stage.
Adjusted for disease, disease status, recipient age at transplantation, and stratified by performance score, use of antithymocyte globulin in conditioning, and years of transplantation.